Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on November 16, 2022. The report serves as a Regulation FD disclosure regarding the announcement of interim results from a clinical study for the company's product, UroShield. The filing incorporates a press release dated November 16, 2022, as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a clinical development update rather than financial performance.
Material Changes
The material event reported is the release of interim clinical study results for UroShield. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release detailing the interim study results. The filing explicitly states that the company undertakes no obligation to update, supplement, or amend the materials attached to this report.
Risks and Contingencies: The document notes that the information furnished pursuant to Item 7.01 shall not be deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It also clarifies that the information will not be incorporated by reference into any filings under the Securities Act or the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 16, 2022) for the specific details of the UroShield interim clinical study results.
- Verify the company's current stock trading status on the Nasdaq Capital Market under the symbol NAOV.
- Check subsequent filings for any updates, as the company has disclaimed an obligation to update this specific disclosure.
- Confirm the identity of the registrant as NanoVibronix, Inc. (Delaware corporation), noting the discrepancy in the request metadata which listed "Envue Medical, Inc."